Harpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' pack
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides (NNVC) +11%. Travere Therapeutics (TVTX) +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix (CMRX) -58%. Eliem Therape
H.C. Wainwright Thinks Leap Therapeutics’ Stock is Going to Recover
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Leap Therapeutics (LPTX – Research Report), with a price target of $4.00. The company's shares close
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ:PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.Po
Mizuho Securities Thinks Leap Therapeutics’ Stock is Going to Recover
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target of $6.00. The company's shares closed last Friday at $1.20,
Thinking about buying stock in Eos Energy Enterprises, Payoneer Global, Leap Therapeutics, Moneylion, or Indie Semiconductor?
NEW YORK, May 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, PAYO, LPTX, ML, and INDI.
Leap Therapeutics GAAP EPS of -$0.09 beats by $0.01
Leap Therapeutics press release (NASDAQ:LPTX): Q1 GAAP EPS of -$0.09 beats by $0.01.Cash and cash equivalents totaled $103.2 million at March 31, 2022.Shares +2.73% PM.
Leap Therapeutics Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia
Leap Therapeutics Q1 Net Loss $10.4M vs Loss $9.1M In Same Qtr. Last Year, Sales $400.00K Up From $375.00K YoY
Leap Therapeutics (NASDAQ:LPTX) reported $400.00 thousand in sales this quarter. This is a 6.67 percent increase over sales of $375.00 thousand the same period last year.
Press Release: Leap Therapeutics Reports First -2-
regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual proper
Press Release: Leap Therapeutics Reports First Quarter 2022 Financial Results
Leap Therapeutics Reports First Quarter 2022 Financial Results PR Newswire CAMBRIDGE, Mass., May 13, 2022 CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: